Recruiting NA INTERVENTIONAL 2-arm NCT06190301

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Randomized Controlled Trial

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University

Conditions Primary Ocular Adnexal MALT Lymphoma

Interventions Involved Site Radiation Therapy Rituximab

Updated 6 times since 2024 Last updated: Oct 29, 2024 Started: Jan 11, 2024 Primary completion: Dec 31, 2029 Completion: Dec 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06190301, this NA trial focuses on Primary Ocular Adnexal MALT Lymphoma and remains actively recruiting participants. Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University, it has been updated 6 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Dec 2024 — Present [monthly]

Recruiting NA
Sep 2024 — Dec 2024 [monthly]

Recruiting NA
Aug 2024 — Sep 2024 [monthly]

Recruiting NA
Jul 2024 — Aug 2024 [monthly]

Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2024 — Mar 2024 [monthly]

Not Yet Recruiting NA

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhongshan Ophthalmic Center, Sun Yat-sen University

Data source: Zhongshan Ophthalmic Center, Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China
• Zhengzhou, China